Literature DB >> 16203767

Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer.

Hisashi Nagahara1, Koshi Mimori, Tohru Utsunomiya, Graham F Barnard, Masaichi Ohira, Kosei Hirakawa, Masaki Mori.   

Abstract

PURPOSE: Human kallikrein genes (KLK) have been reported to be involved in human malignancies and several KLKs are promising biomarkers of prostate, ovarian, testicular, and breast cancers. Herein, we investigated the clinicopathologic and biological significance of KLK6 gene expression in human gastric cancer. PATIENTS AND METHODS: Using real-time reverse transcription-PCR, we analyzed the KLK6 expression status with respect to various clinicopathologic variables in 66 patients with gastric cancer. In addition, we established a KLK6 stably suppressed gastric cancer cell line (MKN28) using small interfering RNA-mediated gene silencing, and investigated its effects on the cell proliferation rate, cell cycle, and invasiveness.
RESULTS: The KLK6 gene expression in cancerous tissue (0.37 +/- 0.53) was significantly (P < 0.000001) higher than that in noncancerous tissue (0.026 +/- 0.060). Elevated KLK6 expression was significantly associated with lymphatic invasion (P = 0.03). Furthermore, patients with a high KLK6 expression had a significantly poorer survival rate than those with a low KLK6 expression (P = 0.03). Therefore, we showed that KLK6 gene silencing with KLK6 small interfering RNA effectively suppressed the cell proliferation rate (P = 0.002), cell population in the S phase (P < 0.01), and invasiveness (P < 0.01) in comparison to mock-transfected cells.
CONCLUSIONS: The KLK6 gene is markedly overexpressed in gastric cancer tissue and its expression status may be a powerful prognostic indicator for patients with gastric cancer. Our findings also suggest that KLK6 may possibly be a novel target for gastric cancer therapy by gene-silencing procedures.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16203767     DOI: 10.1158/1078-0432.CCR-05-0943

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

1.  Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer.

Authors:  Jin Ju Kim; Jong-Tae Kim; Hyo Ran Yoon; Min Ah Kang; Joo Heon Kim; Young-Ha Lee; Jae Wha Kim; Seon-Jin Lee; Eun Young Song; Pyung Keun Myung; Hee Gu Lee
Journal:  Tumour Biol       Date:  2012-02-29

2.  Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.

Authors:  Maroulio Talieri; Marita Zoma; Marina Devetzi; Andreas Scorilas; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-04-03

3.  Clinical significance of human kallikrein 12 gene expression in gastric cancer.

Authors:  En-Hao Zhao; Zhi-Yong Shen; Hua Liu; Xin Jin; Hui Cao
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

4.  SILAC-based quantitative proteomic analysis of gastric cancer secretome.

Authors:  Arivusudar Marimuthu; Yashwanth Subbannayya; Nandini A Sahasrabuddhe; Lavanya Balakrishnan; Nazia Syed; Nirujogi Raja Sekhar; Teesta V Katte; Sneha M Pinto; Srinivas M Srikanth; Praveen Kumar; Harsh Pawar; Manoj K Kashyap; Jagadeesha Maharudraiah; Hassan Ashktorab; Duane T Smoot; Girija Ramaswamy; Rekha V Kumar; Yulan Cheng; Stephen J Meltzer; Juan Carlos Roa; Raghothama Chaerkady; T S Keshava Prasad; H C Harsha; Aditi Chatterjee; Akhilesh Pandey
Journal:  Proteomics Clin Appl       Date:  2013-05-21       Impact factor: 3.494

5.  Silencing of kallikrein-related peptidase 6 attenuates the proliferation, migration, and invasion of gastric cancer cells through inhibition of epithelial-mesenchymal transition.

Authors:  Dong Zhou; Yanping He; Hengping Li; Weidong Huang
Journal:  Exp Ther Med       Date:  2021-05-17       Impact factor: 2.447

6.  Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma.

Authors:  Spyridon Christodoulou; Dimitra K Alexopoulou; Christos K Kontos; Andreas Scorilas; Iordanis N Papadopoulos
Journal:  Tumour Biol       Date:  2014-01-16

7.  Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells.

Authors:  Rebecca S Henkhaus; Upal Kunal Basu Roy; Dora Cavallo-Medved; Bonnie F Sloane; Eugene W Gerner; Natalia A Ignatenko
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

8.  Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.

Authors:  Rebecca S Henkhaus; Eugene W Gerner; Natalia A Ignatenko
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

9.  Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer.

Authors:  David L Kolin; Keiyan Sy; Fabio Rotondo; Mena N Bassily; Kalman Kovacs; Christine Brezden-Masley; Catherine J Streutker; George M Yousef
Journal:  Tumour Biol       Date:  2015-07-30

10.  KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.

Authors:  Konstantinos G Sidiropoulos; Qiang Ding; Georgios Pampalakis; Nicole M A White; Peter Boulos; Georgia Sotiropoulou; George M Yousef
Journal:  Mol Oncol       Date:  2016-04-08       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.